Leyden Labs Adds €40m for Intranasal Flu Prevention - European Biotechnology Magazine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Gates Foundation backs Leyden Labs’ €40M raise: Can a nasal spray do what 80 years of flu vaccines couldn’t
Leyden Labs has raised 40 million euros from the Gates Foundation, EIC Fund, Invest-NL, and ClavystBio to advance its pan-influenza nasal spray through clinical trials. The Gates Foundation joins as a first-time investor, with a specific mandate to expand access to Leyden’s products in low- and middle-income countries. The raise brings Leyden Labs’ total funding to over $336M, making it one of the best-capitalised respiratory virus biotechs outs…
Leyden Labs adds €40m for intranasal flu prevention - European Biotechnology Magazine
Dutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses. The post Leyden Labs adds €40m for intranasal flu prevention appeared first on European Biotechnology Magazine.
Biotech company Leyden Labs, which manufactures nasal sprays against viruses, has received 40 million euros from international investors. The Leiden-based biotech company Leyden Labs has raised 40 million euros from a consortium of international investors. The start-up announced this in a press release on Thursday morning. Investors include the European Innovation Council Fund, Invest-NL, the Gates Foundation, and ClavystBio, among others. Form…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
